Vernalis to Present at Piper Jaffray 19th Annual Healthcare Conference
12 November 2007
Vernalis plc (LSE: VER) today announced that Mr. Simon Sturge, Chief Executive Officer, and Mr. Tony Weir, Chief Financial Officer, will participate in The Piper Jaffray 19th Annual Healthcare Conference in New York. Mr. Sturge is scheduled to present an overview of the Company’s business activities and product pipeline, as well as, meet with investors.
The conference will be held 27–29 November, 2007 at The Pierre Hotel in New York. Vernalis is scheduled to present at 4.00 pm Eastern time on 27 November. To listen to the audio webcast of the presentation, please visit: http://www.piperjaffray.com/conferences.
-- ends --
Enquiries:
|
Vernalis plc |
+44 (0) 118 977 3133 |
|
Simon Sturge, Chief Executive Officer |
|
|
Tony Weir, Chief Financial Officer |
|
|
|
|
|
Brunswick Group |
+44 (0) 20 7404 5959 |
|
Jon Coles |
|
|
Justine McIlroy |
|
|
Alex Tweed |
|
|
|
|
|
Lazar Partners Ltd |
|
|
Gregory Gin |
+1 212-867-1762 |
Notes to Editors
About Vernalis
Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has has established a US commercial operation to promote Apokyn ® and co-promote Frova ® alongside its North American licensing partner, Endo Pharmaceuticals. The company has seven products in clinical development focused on neurology and central nervous system disorders and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Chiesi. For further information about Vernalis, please visit www.vernalis.com.
|
Product |
Indication |
Phase I |
Phase II |
Phase III |
Registration |
Market |
Marketing Rights |
|
Apokyn® |
Parkinson’s Disease |
|
|
|
|
X |
North America |
|
Frova® |
Migraine |
|
|
|
|
X |
US Co-promotion Endo (EU-royalties) |
|
Frova® |
Menstrual Migraine Prevention |
|
|
|
X |
|
US Co-promotion Endo (EU-royalties) |
|
V1512 |
Parkinson’s Disease |
|
X |
|
|
|
World Wide (excl. Italy) |
|
V10153 |
Thrombotic Disorders |
|
X |
|
|
|
World Wide |
|
V3381 |
Neuropathic Pain |
|
X |
|
|
|
World Wide |
|
V2006 |
Parkinson’s Disease |
|
X |
|
|
|
US Co-promotion Biogen Idec |
|
V24343 |
Obesity |
X |
|
|
|
|
World Wide |
|
Hsp90 |
Cancer |
X |
|
|
|
|
None – royalty (Novartis) |
Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova® and Apokyn® and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
